ASPIRE Quality Committee
Meeting
February 24th, 2020
Agenda
• Upcoming Events and Announcements
• Plans for 2020
• Import Manager Conversion deadline
• Measure Updates
• DataDirect, Dashboard 2.0
• Dynamic Measure Spec
• OB and Peds Update
• VBR Update
• ABA/MOCA Project Update
• Health Disparities and MPOG
2020 Quality
Committee
Meetings on
Monday
Meeting Minutes
November 2019
Upcoming Event
ASPIRE/MSQC
Collaborative Meeting
March 27, 2020
Agenda
• ACQR Breakout
• ASPIRE Performance Review
• Sustainability in the OR
• Perspective from a participant in MIPACT
Tom Varghese, MD Dan Clauw, MD Eve Kerr, MD
ASPIRE Summer Meeting
July 17
th
2020
Mark your calendars
MI Hospitals
P4P
Legacy Extract No
Longer Supported in
2020
Import Manager: Convert all sites by 12/31/2021
• Import Manager is the current method used to move data from the electronic health records
into MPOG
• Allows sites to also add data outside of the anesthesia record (Preop/PACU/etc)
• Conversion takes approximately 6 months to 1 year
• All sites using ‘legacy’ extract must convert by 12/31/2021
– As of 1/1/2022, legacy sites will no longer be able to upload data to MPOG Central until converted
– Legacy sites will still be able to access their dashboard, but it will no longer be updated with new data after
1/1/2022
– Legacy sites will no longer receive provider feedback emails as of 1/1/2022 until converted
– Application Suite upgrades will only be compatible with Import Manager as of 1/1/2022
Legacy Extract Sites to Convert
• Bronson Battle Creek/Kalamazoo
• Cleveland Clinic
• Columbia
• Memorial Sloan Kettering
• NYU Langone
• Sparrow Health System
• Stanford
• University of Arkansas
• University of Colorado
• University of Pennsylvania
• University of Tennessee
• University of Utah
• University of Vermont
• University of Washington
• Wake Forest
• Weill Cornell
• Yale
VBR (Value Based
Reimbursement) Update
BCBS Value Based Reimbursement Program
• 2020 BCBS VBR Program
– Performance Period: December 1, 2018- November 30, 2019
– To be eligible:
– Member of a PO for at least 1 year
– Have at least 2 years of data in ASPIRE
– Aggregate hospital performance meets target for 2 out of 3 measures: PUL 02 ≥ 70%, TEMP 03 ≥ 90% , TOC 02 ≥ 90%
– Physicians are assigned to hospital where they have performed the most cases
– 3% applied starting March 1, 2020 to anesthesiologist provider payments for all cases
• 2021 BCBS VBR Program
– Performance Period: January 1, 2020-November 30, 2020
– To be eligible:
– Member of a PO for at least 1 year
– Have at least 2 years of data in ASPIRE
– Aggregate hospital performance meets target for 2 out of 3 measures: PUL 02 ≥ 85%, TEMP 03 ≥ 95%, PONV 01 ≥ 85%
– Physicians are assigned to hospital where they have performed the most cases
MPOG Obstetric
Anesthesia
Subcommittee
MPOG Obstetric Anesthesia Subcommittee
• Reconvened December 11, 2019
• 12 obstetric anesthesiologists in attendance (21 members total)
• Currently, 35 sites submit cesarean delivery data to MPOG
• Labor epidural conversion to c-section: difficult to identify using CPT codes alone
– MPOG creating ‘phenotype’ to identify these cases using notes/medications before building obstetric specific
measures
• Committee selected three OB-specific measures to build for 2020:
– Antibiotic Timing for Cesarean Deliveries
– Antibiotic Selection for Cesarean Deliveries
– Prolonged Hypotension for Cesarean Deliveries
• Next meeting to be scheduled for March 2020: Reviewing OB ABX 01 Measure Specification
1
st
Obstetric Anesthesia Measure:
Antibiotic Timing for Cesarean Delivery (OB ABX 01)
Description: Percentage of cesarean deliveries with documentation of antibiotic
administration initiated within one hour before surgical incision
Inclusions:
– Elective, urgent, or emergent cesarean delivery (CPT: 01961 & 01968)
– Patients undergoing cesarean section with hysterectomy (CPT: 01969)
– Labor epidural cases converted to cesarean delivery
Exclusions:
– Obstetric Non-Operative Procedures – CPT 01958, 01960, 01967 (without 01968)
– Cesarean delivery with documentation of infection prior to incision and mapped to one of the following MPOG concepts:
• 50181 Compliance- Prophylactic Antibiotic Variance Note
• 50182 Compliance- Prophylactic Antibiotic Variance Note Detail
Responsible Provider: All anesthesia providers signed in at the time of incision. If uterine
incision time is not documented (50357) then providers signed in at the procedure start time
(50006) will be attributed.
Antibiotic Timing for Cesarean Delivery (OB ABX 01)
Antibiotic MPOG Concept Appropriate Start Time
Azithromycin 10048 Between Anesthesia Start and Anesthesia End
Cefazolin 10107 Within 60 minutes before incision
Cefepime 10108 Within 60 minutes before incision
Cefotaxime 10109 Within 60 minutes before incision
Cefotetan 10110 Within 60 minutes before incision
Cefoxitin 10111 Within 60 minutes before incision
Ceftriaxone 10114 Within 60 minutes before incision
Cefuroxime 10115 Within 60 minutes before incision
Clindamycin 10131 After cord clamping; if not available, after delivery of neonate;
(consider any time between anes start and end)
Gentamicin 10202 Within 60 minutes before incision
Vancomycin 10444 Within 120 minutes before incision
Acceptable Antibiotics and Associated Timing*:
*Emergency cases: Any of the above antibiotics initiated between anesthesia start and anesthesia end
ASPIRE Pediatric
Subcommittee Update
ASPIRE Pediatric Subcommittee Update
• Peds group reconvened December 2019
– 23 Pediatric Anesthesiologists were in attendance
– Increasing numbers of pediatric cases in the database (1.4m at
last count)
– Proposed formation of SPA quality metric workgroup to inform
the MPOG Pediatric subcommittee of best practices in pediatric
anesthesia.
• 2020 plans: build 2-3 pediatric specific measures
– Temperature management
– Add tonsillectomy and spine cases to opioid equivalency
dashboard
– Postoperative respiratory complications
– Intraoperative hypotension (informational measure)
• If Interested in joining, please contact Meridith Bailey
(
Meridith@med.umich.edu)
Measure Development: PEDS Temp (Informational)
• Description: Percentage of patients < 18 years old who undergo a surgical or therapeutic
procedure whom have a body temperature (core or peripheral) less than 36 or ≥ 38 degrees
Celsius consecutively for ≥ 15 minutes between patient in room and one hour after
Anesthesia End.
• Measure Time Period: Patient in OR to 1 hour after Anesthesia End
• Exclusions:
– ASA 5 and 6
– Anesthesia for diagnostic or therapeutic nerve blocks/injections (CPT: 01991, 01992)
– Unlisted Anesthesia procedure (CPT: 01999)
– Organ Harvest (CPT: 01990)
– Obstetric Non-Operative Procedures (CPT: 01958, 01960, 01967)
– Cardiac Surgery (CPT: 00561, 00562, 00563, 00566, 00567, 00580)
– Emergency cases (MPOG concepts: 70142 or 515)
Measure Build: PEDS Temp
• Success: All body temperature measurements (core or peripheral) from Patient in room to
one hour after anesthesia end are between 36 and 37.9 degrees Celsius.
• Artifact Algorithm:
– Less than 32.0˚C (89.6F)
– Greater than 40.0˚C (104.0F)
– Any minute-to-minute jumps >0.5˚C equivalent.
– Example: 0.125˚C /15s, 0.25˚C / 30s, 1˚C / 2mins
• Responsible Provider: Provider present for the longest duration of the case per staff role.
Measure Updates
Updated Glycemic Management Measures
• GLU 01 (high glucose treated or remeasured) and GLU 02 (low glucose treated or
remeasured) evaluate intraoperative management only
• MPOG now receives preoperative and PACU medication and fluid data for several Import
Manager sites
• GLU 03 – High glucose rechecked or treated during the perioperative period (preop through
PACU)
• GLU 04 - Low glucose rechecked or treated during perioperative period (preop through
PACU)
• Sites can add GLU 03 and GLU 04 based on when preop and PACU medication data was
submitted to MPOG (>50% of cases have preop/PACU meds)
• Will continue to see historical data for GLU 01 and GLU 02 in dashboard
PONV Outcome Measure
• PONV 03 – Postoperative Nausea and Vomiting Outcome
– Cases flagged if
– Rescue anti-emetic administered
– Patient reported nausea
– Patient has documented episode of emesis
• PONV 03B- Subset of PONV 03 Measure
– Removes rescue anti-emetic administration from ‘flagged’ criteria
– Cases flagged for PONV03B if
– Anti-emetic administered
– Patient reported nausea
– Patient has documented episode of emesis
PONV Changes
• PONV 03 Dexamethasone and Methylprednisolone have also been removed from the list of
rescue anti-emetics considered
• PONV 01/02 now exclude patients who are transferred directly to ICU to exclude patients
who remain intubated postoperatively
Feedback for PONV 01/02: Meclizine as prophylaxis
• Meclizine is not currently considered as an anti-emetic in our measures
• Society for Ambulatory Anesthesiology Consensus Guidelines for the Management of
Postoperative Nausea and Vomiting 2014
– “Meclizine has a longer duration of PONV effect than ondansetron. Meclizine 50mg per os plus ondansetron
4mg IV is more effective than either ondansetron or meclizine alone”
• Limited evidence
• PO Meclizine given the night before surgery and/or in preop along with intraoperative
ondansetron reduces nausea following discharge
– Bopp et al (2010). Biphasic dosing regimen of meclizine for prevention of postoperative nausea and vomiting
in a high-risk population. AANA Journal, 78(1), 55–62.
– Forrester et al (2007). Meclizine in Combination with Ondansetron for Prevention of Postoperative Nausea
and Vomiting in a High-Risk Population. AANA Journal, 75(1), 27–33.
Application Updates
DataDirect
• New version rolled out last
month
• Able to add measure
performance to output for your
own institution
• Next up: revising the filtering
section: June 2020
Dashboard 2.0
FLEXIBLE VISUALLY INTERESTING LINKS TO OTHER MPOG
APPS
ABA-MOCA Project Introduction
Benjamin Cloyd MD, MIPH
Clinical Lecturer
University of Michigan Department of Anesthesiology
2019-2021 FAER-ABA Research in Education Grant Awardee
• FAER-ABA Research
in Education Grant
• Seeking to evaluate the value of primary certification and
the Maintenance of Certification in Anesthesiology™
program (MOCA®) to clinicians and the public, including
assessment of how certification is related to clinical
performance and novel means to analyze and utilize data.
What We’d Like To Do
• Part of the ASPIRE Mission:
• “Our goal is to improve the care of patients undergoing anesthesia by
reducing unexplaine d variation in practice and collaborating with anesthesia
providers to define best practices.”
• We would like to study the distribution of performance amongst
anesthesia providers and institutions at ASPIRE institutions within the
state of Michigan.
Why We Are Doing This
• Continue to evaluate and improve our ASPIRE metrics.
• Develop a different pathway to research and spread ASPIRE findings
and best practices.
• Utilize the performance distribution data to evaluate which ASPIRE
metrics may be useful for research projects and further analysis.
Who We Are
• Nirav Shah MD
• Lauryn Rochlen MD
• Sachin Kheterpal MD, MBA
• Katie Buehler MS, RN, CPPS
• Graciela Mentz, PhD
• Allison Janda MD
• Allie Leis MS
• Genevieve Bell BS
• Douglas Colquhoun MB ChB, MPH
• The ABA and collaborators at other institutions
A big team is interested in this with major contributions from:
How Can We Collaborate?
• Entering data matching phase of the primary project.
• The ABA and FAER are currently in the process of the second grant
cycle and interesting follow-up ideas have been proposed.
Questions, Thoughts, and Opportunities
Thank you
